AD: Shocked! The peak value of plasma Aβ42/Aβ40 began to decline 41 years before the deposition of brain Aβ! Alzheimer's diseases: New discovery on plasma Aβ42/Aβ40. AD: Shocked! The peak value of plasma Aβ42/Aβ40 began to decline 41 years before the deposition of brain Aβ! Amyloid β (Aβ) plaque deposition and phosphorylated tau (p-tau) protein tangles are two important pathological features of Alzheimer's disease (AD), and there are many kinds of AD biomarkers derived around them, Knowledge of the longitudinal trajectories of key markers could not only help improve the selection and monitoring of participants in clinical trials, but also help identify those at high risk for neurodegenerative changes and cognitive impairment. Although research on AD biomarkers has increased substantially in recent years, research on longitudinal changes in biomarkers is relatively limited. Studies have shown that the levels of plasma Aβ 42 /Aβ 40 , p-tau181 and glial fibrillary acidic...
AstraZeneca's Farxiga (Dapagliflozin) in the treatment of severe complications and high-risk COVID-19 hospitalized patients Phase 3 study failed!
AstraZeneca's Farxiga (Dapagliflozin) in the treatment of severe complications and high-risk COVID-19 hospitalized patients Phase 3 study failed!
As of 0:00 on April 13, 2021, more than 130 million (13.77 million) cases have been diagnosed globally and more than 2.95 million deaths.
Recently, AstraZeneca and Saint Luke’s Mid America Heart Institute announced the high-level results of the preliminary analysis of the DARE-19 global phase III trial. The trial evaluated the potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor Farxiga (Chinese trade name: Andatang, generic name: dapagliflozin, dapagliflozin) in the treatment of COVID-19 hospitalized patients who are at risk of serious complications .
The results showed that at 30 days, the trial did not reach statistical significance in terms of the main prevention endpoints for measuring organ dysfunction and all-cause mortality, and the main recovery endpoints for measuring changes in clinical status (from early recovery to death). In the 30-day trial, the safety and tolerability of Farxiga were consistent with the known safety of the drug. The complete DARE-19 trial results will be announced at the American College of Cardiology (ACC) scientific meeting in May 2021.
DARE-19 is the first phase 3 clinical trial to evaluate the safety and effectiveness of SGLT2 inhibitors in the treatment of COVID-19 hospitalized patients with risk factors for serious complications. Risk factors for serious complications in these patients include: hypertension (HTN), type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), stage 3-4 chronic kidney disease Disease (CKD). The purpose of the trial is to evaluate whether Farxiga can reduce the risk of disease progression, clinical complications and death caused by COVID-19 in patients with cardiovascular (CV), metabolic or renal risk factors.
Heart, kidney, and metabolic comorbidities are related to the poor prognosis and death of COVID-19 patients. The trial design is supported by a large amount of data on the protective effects of Farxiga on patients with heart failure (HFrEF), chronic kidney disease (CKD) or type 2 diabetes (T2D) with reduced ejection fraction.
Mikhail N. Kosiborod, MD, chief investigator of the DARE-19 study and cardiologist at St. Luke’s Central American Heart Institute, said: “The DARE-19 study provides important information on the potential benefits and risks of using SGLT2 inhibitors for the treatment of COVID-19 inpatients. Data. Although the trial did not reach statistical significance, the results of the study are very interesting and valuable, and will provide information for future clinical science. In addition, it is important that we understand the good safety of dapagliflozin in the DARE-19 study It's consistent."
Mene Pangalos, executive vice president of R&D at AstraZeneca Biopharmaceuticals, said: "Before the DARE-19 Phase III trial, there was almost no data on the use of SGLT2 inhibitors in COVID-19 hospitalized patients. We have now helped fill this knowledge gap. We look forward to publishing efficacy and safety data in the coming weeks."
DARE-19 is an international, parallel group, randomized, double-blind, placebo-controlled, investigator-sponsored Phase III trial. It was carried out in adult patients hospitalized with COVID-19 at the time of trial entry, and these patients also had hypertension ( HTN), atherosclerotic cardiovascular disease (ASCVD), heart failure with reduced or preserved ejection fraction (HFrEF or HFpEF), type 2 diabetes (T2D), stage III or IV chronic kidney disease (CKD) disease history. In the study, all patients received background local standard care treatment in order to assess the impact of Farxiga on the risk of all-cause death or disease progression and complications. The main efficacy endpoint of the study is: the time to the first all-cause death or new/worsening organ dysfunction during the 30-day follow-up period.
Forxiga's active pharmaceutical ingredient is dapagliflozin (dapagliflozin), which is a first-of-its-kind, oral, once-daily, selective sodium-glucose cotransporter (SGLT2) inhibitor, which has been approved for use in adults with type 2 diabetes The patient improves blood sugar control. The drug acts independently of insulin and selectively inhibits SGLT2 in the kidneys, which can help patients excrete excess glucose from the urine. In addition to lowering blood sugar, the drug also has the additional benefits of weight loss and lowering blood pressure. The DECLARE CV outcome trial in adult patients with type 2 diabetes (T2D) showed that compared with placebo, Farxiga reduced the risk of heart failure (HF) hospitalization or cardiovascular (CV) death composite end point.
Some of the patients at the highest risk of complications from COVID-19 appear to be patients with cardiometabolic diseases. Cardiovascular complications, including acute myocardial injury and heart failure (HF) are common in COVID-19 patients and seem to be a key factor leading to poor prognosis and death, especially in patients with underlying cardiovascular disease and/or CKD